FDA expands use of Allergan's Botox to include overactive bladder

01/20/2013 | Reuters · MedPage Today (free registration)

Allergan's Botox, or onabotulinumtoxin A, has been approved by the FDA for use in patients with overactive bladder who can't take or don't improve with anticholinergics. The approval was based on results of two clinical studies showing that Botox reduced the frequency of incontinence and urination compared with placebo.

View Full Article in:

Reuters · MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD